Producción de BeNToglucerasa para el tratamiento no invasivo de la enfermedad de Gaucher
- Cotán, D.
- Luque Villalta, José Carlos
- Infante Viñolo, Juan José
ISSN: 2254-3821
Year of publication: 2013
Issue: 2
Type: Article
More publications in: Biosaia: Revista de los másteres de Biotecnología Sanitaria y Biotecnología Ambiental, Industrial y Alimentaria
Sustainable development goals
Bibliographic References
- Begley, D., Pontikis, C., & Scarpa, M. (2008). Lysosomal Storage Diseases and the Blood-Brain Barrier. Current Pharmaceutical Design, 14(16), 1566–1580. doi:10.2174/138161208784705504
- Giraldo, P., & Roca, M. (2011). [Therapeutic targets in Gaucher's disease]. Medicina clínica, 137 Suppl 1, 46-49. doi:10.1016/S0025-7753(11)70017-3
- Lee, J.-Y., Lee, B. H., Kim, G.-H., Jung, C.-W., Lee, J., Choi, J.-H., & Yoo, H.-W. (2012). Clinical and genetic characteristics of Gaucher disease according to phenotypic subgroups. Korean journal of pediatrics, 55(2), 48-53. doi:10.3345/kjp.2012.55.2.48
- Vaags, A. K., Campbell, T. N., & Choy, F. Y. M. (2005). HIV TAT variants
- Vairo, F., Netto, C., Dorneles, A., Mittelstadt, S., Wilke, M., Doneda, D. Schwartz, I. V.D.(2013). Enzyme Replacement Therapy in a Patient with Gaucher Disease Type III: A Paradigmatic Case Showing Severe Adverse Reactions Started a Long Time After the Beginning of Treatment. JIMD reports. doi:10.1007/8904_2013_214